Latest Conference Articles

A thriving gut microbiome is associated with better clinical outcomes after CAR T-cell therapy for lymphoma and myeloma.

Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in high-risk pediatric ALL.

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML.

Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

Research from Samuel Shangwu Wu, PhD, presented as an ADA Presidents' Select Abstract, proposes a better way to measure beta-cell preservation.

Remote therapeutic monitoring with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guidelines and reimbursement to make it standard of care.

Four experts examine what updated dietary and obesity guidelines mean for diabetes care, and why personalized, equitable nutrition is now essential.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

Diet quality, carbohydrate quantity, and macronutrient composition may influence gestational glycemia, with consequences well into the postpartum period.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

Two new studies reveal how social determinants shape cognitive risk in prediabetes and type 2 diabetes, complicating the path to prevention.

Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and policy barriers to equitable care.

At ADA 2026, Alyson K. Myers, MD, explains why knowing your community—and meeting patients where they are—is key to better diabetes outcomes and lower costs.

AI tools for carbohydrate estimation and clinical decision support are reshaping how diabetes is managed, but human oversight remains essential.

ADA 2026: Inhaled insulin (Afrezza) shows comparable HbA1c and time-in-range to rapid-acting analogs in youth, with greater treatment satisfaction reported.

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.